Malaria in Brazil: what happens outside the Amazonian endemic region.

Mem Inst Oswaldo Cruz

Centro de Pesquisa, Diagnóstico e Treinamento em Malária, Reference Laboratory for Malaria in the Extra-Amazonian Region for the Brazilian Ministry of Health, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, Brasil.

Published: August 2014

Brazil, a country of continental proportions, presents three profiles of malaria transmission. The first and most important numerically, occurs inside the Amazon. The Amazon accounts for approximately 60% of the nation's territory and approximately 13% of the Brazilian population. This region hosts 99.5% of the nation's malaria cases, which are predominantly caused by Plasmodium vivax (i.e., 82% of cases in 2013). The second involves imported malaria, which corresponds to malaria cases acquired outside the region where the individuals live or the diagnosis was made. These cases are imported from endemic regions of Brazil (i.e., the Amazon) or from other countries in South and Central America, Africa and Asia. Imported malaria comprised 89% of the cases found outside the area of active transmission in Brazil in 2013. These cases highlight an important question with respect to both therapeutic and epidemiological issues because patients, especially those with falciparum malaria, arriving in a region where the health professionals may not have experience with the clinical manifestations of malaria and its diagnosis could suffer dramatic consequences associated with a potential delay in treatment. Additionally, because the Anopheles vectors exist in most of the country, even a single case of malaria, if not diagnosed and treated immediately, may result in introduced cases, causing outbreaks and even introducing or reintroducing the disease to a non-endemic, receptive region. Cases introduced outside the Amazon usually occur in areas in which malaria was formerly endemic and are transmitted by competent vectors belonging to the subgenus Nyssorhynchus (i.e., Anopheles darlingi, Anopheles aquasalis and species of the Albitarsis complex). The third type of transmission accounts for only 0.05% of all cases and is caused by autochthonous malaria in the Atlantic Forest, located primarily along the southeastern Atlantic Coast. They are caused by parasites that seem to be (or to be very close to) P. vivax and, in a less extent, by Plasmodium malariae and it is transmitted by the bromeliad mosquito Anopheles (Kerteszia) cruzii. This paper deals mainly with the two profiles of malaria found outside the Amazon: the imported and ensuing introduced cases and the autochthonous cases. We also provide an update regarding the situation in Brazil and the Brazilian endemic Amazon.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156455PMC
http://dx.doi.org/10.1590/0074-0276140228DOI Listing

Publication Analysis

Top Keywords

malaria
12
cases
11
profiles malaria
8
malaria cases
8
cases caused
8
imported malaria
8
introduced cases
8
amazon
6
region
5
malaria brazil
4

Similar Publications

Guillain-Barré syndrome following falciparum malaria infection: a case report.

BMC Neurol

January 2025

Department of Radiology, School of Medicine, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Teferi, Ethiopia.

Background: Malaria is an infectious disease caused by Plasmodium parasites, transmitted to humans by infected female Anopheles mosquitoes. Five Plasmodium species infect humans: P. vivax, P.

View Article and Find Full Text PDF

Background: The negative impact of COVID-19 pandemic on healthcare service utilization has been reported in several countries. In Gabon, data on the preparedness for future pandemic are lacking. The aim of the present study was to assess the trends of hospital attendance, malaria and self-medication prevalences as well as ITN use before and during Covid-19 first epidemic waves in a paediatric wards of a sentinel site for malaria surveillance, in Libreville, Gabon.

View Article and Find Full Text PDF

First evidence of human infection by the kinetoplastid flagellate Dimastigella trypaniformis in a patient with urinary tract infection.

Int J Infect Dis

January 2025

Molecular Microbiology Laboratory, Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. Electronic address:

We present a case of an 88-year-old man with symptoms consistent with a urinary tract infection, whose diagnostic workup uncovered a previously unrecognized motile flagellated protozoan. Molecular identification confirmed the organism as Dimastigella trypaniformis, a free-living kinetoplastid from the Rhynchomonadidae family. Known only from soil samples in Scotland and termite gut contents in Australia and Germany, Dimastigella trypaniformis has not been previously reported to infect vertebrate hosts.

View Article and Find Full Text PDF

Clarification of factors associated with post-artesunate delayed hemolysis (PADH): analysis of 327 patients with severe imported Plasmodium falciparum malaria in France.

Travel Med Infect Dis

January 2025

Centre National de Référence du Paludisme, Paris, France; Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM U1018, Paris, France; Université Paris-Saclay, Service des Maladies infectieuses et tropicales, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Société Française de Médecine des Voyages.

Background: Post-Artesunate delayed hemolysis (PADH) occurs in approximately 15% of treated patients 2 to 3 weeks after artesunate administration. Identifying risk markers for PADH would help predict which patients are at higher risk.

Methods: In this prospective national cohort study conducted in a non-malaria endemic area from 2011 to 2016, a Cox proportional hazards model was used to assess the association between clinical and biological data available at Day 0 and the occurrence of PADH within 30 days of artesunate administration.

View Article and Find Full Text PDF

Background: The World Health Organization conditionally recommends reactive drug administration to reduce malaria transmission in settings approaching elimination. However, few studies have evaluated the impact of reactive focal drug administration (rFDA) in sub-Saharan Africa, and none have evaluated it under programmatic conditions. In 2016, Senegal's national malaria control programme introduced rFDA, the presumptive treatment of compound members of a person with confirmed malaria, and reactive mass focal drug administration (rMFDA), an expanded effort including neighbouring compounds during an outbreak, in 10 low transmission districts in the north of the country.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!